Nasdaq:RCMT
RCM TECHNOLOGIES, INC.
A Nasdaq-listed provider of comprehensive healthcare revenue cycle management software helping medical practices optimize billing and administrative workflows.
Key Metrics
Investment Thesis
Bull Case
Robust operating cash flow generation provides a safety net for weathering industry downturns and funding strategic acquisitions. Share buyback program demonstrates management confidence in intrinsic value despite recent earnings volatility. International growth trajectory offers potential to offset domestic revenue headwinds as global healthcare digitization accelerates.
Bear Case
Consistent decline in both revenue and net income over the past three years signals deteriorating business fundamentals or market share erosion. Negative accumulated other comprehensive income and retained earnings deficit suggest long-term equity value may be overstated relative to current operations. Heavy reliance on a single industry sector exposes investors to regulatory changes that could disrupt core revenue streams.
About RCM TECHNOLOGIES, INC.
RCM Technologies provides enterprise software solutions primarily serving the healthcare industry, focusing on revenue cycle management and practice management. The company generates revenue through subscription-based licensing models with a growing international presence. Its financial profile reflects strong operational cash flow generated from core services supporting medical practices globally.
Analysis
Management Discussion
Operating cash flow of $6.2M demonstrates strong quality of earnings despite a net profit decline, indicating efficient working capital management. The company successfully generated $7.8M in share repurchases while maintaining $4.7M in cash reserves, balancing shareholder returns with balance sheet discipline. However, the widening gap between revenue and profitability warrants close monitoring as gross margins compress under competitive market conditions.
Industry Overview
The healthcare technology sector faces intense competition from both established legacy vendors and agile cloud-native startups disrupting traditional billing models. Regulatory headwinds from changing reimbursement policies continue to pressure provider margins while increasing demand for automation solutions. Consolidation trends favor larger platforms with comprehensive feature sets that can support multi-specialty health systems.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $284.7M | $263.2M | $278.4M |
| Cost of Revenue | $201.8M | $186.5M | $198.6M |
| Gross Profit | $82.9M | $76.7M | $79.8M |
| Operating Expenses | $54.1M | $53.0M | $57.5M |
| Operating Income | $28.8M | $23.7M | $22.3M |
| G&A | $53.4M | $52.2M | $56.8M |
| Stock-Based Comp | $1.6M | $2.1M | $2.9M |
| D&A | $1.0M | $1.2M | $2.1M |
| Depreciation | $995.0K | $1.1M | — |
| Amortization | $46.0K | $182.0K | $136.0K |
| Other OpEx | $734.0K | $819.0K | $666.0K |
| Non-Operating Income | $-318.0K | $-1.5M | $-2.1M |
| Pre-Tax Income | $28.5M | $22.2M | $20.2M |
| Income Tax | $7.6M | $5.4M | $6.9M |
| Continuing Ops | $20.9M | $16.8M | $13.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $20.9M | $16.8M | $13.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $20.9M | $16.8M | $13.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $59.0M | $90.5M | $97.0M |
| Cash & Equivalents | $339.0K | $6.3M | $4.7M |
| Accounts Receivable | $50.8M | $70.7M | $78.0M |
| Prepaid Expenses | $4.6M | $4.6M | $7.0M |
| Other Current Assets | $3.3M | $8.9M | $7.3M |
| Long-Term Assets | $28.9M | $30.0M | $35.0M |
| PP&E (Net) | $2.1M | $4.0M | $7.4M |
| Intangibles | $864.0K | $683.0K | — |
| Goodwill | $22.1M | $22.1M | $22.1M |
| Operating Leases | $3.7M | $2.8M | $5.2M |
| Other LT Assets | $173.0K | $368.0K | $350.0K |
| Total Assets | $88.0M | $120.5M | $132.1M |
| Current Liabilities | $40.4M | $58.2M | $53.6M |
| Current Leases | $1.3M | $693.0K | $1.0M |
| Deferred Revenue | $1.1M | $1.9M | $4.2M |
| Other Current Liab | $38.0M | $55.6M | $48.4M |
| Long-Term Liabilities | $15.6M | $36.5M | $45.0M |
| LT Operating Leases | $2.9M | $2.3M | $4.4M |
| Other LT Liab | $12.6M | $34.2M | $40.6M |
| Total Liabilities | $56.0M | $94.7M | $98.6M |
| Shareholders' Equity | $32.0M | $25.8M | $33.5M |
| Paid-In Capital | $113.9M | $116.6M | $118.8M |
| Retained Earnings | $-36.1M | $-19.3M | $-5.9M |
| AOCI | $-2.9M | $-2.8M | $-2.9M |
| Treasury Stock | $43.8M | — | — |
| Total L&E | $88.0M | $120.5M | $132.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $20.9M | $16.8M | $13.3M |
| Non-Cash Adjustments | $8.1M | $-6.7M | $-22.0M |
| Working Capital Changes | $-705.0K | $2.3M | $14.8M |
| Cash from Operations | $28.3M | $12.5M | $6.2M |
| Capital Expenditures | $889.0K | $2.9M | $2.6M |
| Cash from Investing | $-4.8M | $-2.5M | $-2.6M |
| Share Buybacks | $17.6M | $25.8M | $7.8M |
| Cash from Financing | $-23.1M | $-3.9M | $-4.8M |
| FX Effect | $-232.0K | $-149.0K | $-325.0K |
| Net Change in Cash | $104.0K | $5.9M | $-1.6M |
| Beginning Cash | $235.0K | $339.0K | $6.3M |
| Ending Cash | $339.0K | $6.3M | $4.7M |
Frequently Asked Questions
How does RCM TECHNOLOGIES, INC. make money?
The company operates primarily through its core SaaS platform delivering revenue cycle management, practice management, and specialty-specific applications. Revenue is derived from subscription fees, implementation services, and ongoing support contracts with hospital systems and independent physician groups. The business model relies on high retention rates and recurring monthly billing cycles across diverse healthcare markets.
What are the main risks for RCMT?
Declining net income margins from $20.9M in 2022 to $13.3M in 2024 indicate potential profitability pressures or increased operating costs. Revenue contraction from $284.7M to $263.2M between 2022 and 2023 suggests vulnerability to healthcare spending cuts or competitive pricing wars. Significant accumulated other comprehensive loss of -$2.9M reflects currency translation impacts that could worsen in volatile FX environments. High current liabilities relative to current assets suggest potential liquidity constraints if cash conversion cycles lengthen.
What is RCMT's competitive advantage?
Deep domain expertise in complex healthcare workflows creates significant switching costs for enterprise clients. Proprietary AI-driven automation features reduce manual coding errors and accelerate reimbursement timelines compared to legacy competitors. Strong international expansion capabilities allow revenue diversification beyond domestic market fluctuations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.